Latest Strategy Changes News

EML Payments has affirmed its FY26 underlying EBITDA guidance of A$58-63 million following a solid Q1 trading update, underpinned by a growing new program pipeline and operational efficiencies.

Ausgold Limited has raised A$80 million through a fully underwritten placement to fast-track the Katanning Gold Project, aiming for a final investment decision by mid-2026. The capital injection strengthens the company’s balance sheet and supports key development milestones.

Environmental Clean Technologies is set to convert a $1.13 million convertible note into equity, significantly reducing debt and freeing resources to advance its PFAS remediation technology.

White Energy Company Limited has announced a partially underwritten entitlement offer to raise approximately $3.5 million at a 10% discount, aimed at funding key mineral exploration projects across Australia.

Horizon Oil Limited reported robust FY25 results, highlighted by a strategic acquisition of Thailand upstream assets and a 10-year permit extension at Maari, nearly doubling production and securing a strong outlook through 2030.

Talga Group has received official land allocation approval for its Nunasvaara Södra graphite mine in Sweden, a critical step in advancing its sustainable battery materials project.

Narryer Metals reports promising early results using an organic acid to extract rare earth elements at its Rocky Gully project, highlighting potential for cost-effective and sustainable processing.

Larvotto Resources reports a breakthrough 90% tungsten recovery from metallurgical testwork at its Hillgrove project, signaling a new revenue stream alongside gold and antimony production.

Tivan Limited has made significant progress on its Speewah Fluorite Project in Western Australia, completing a major drilling phase and advancing its Feasibility Study, now scheduled for completion in February 2026. The project aims to produce acidgrade fluorspar for global markets, supported by strong joint venture partnerships and strategic financing.

SEEK Limited’s CEO presented the company’s financial guidance for FY2026 during the 2025 Annual General Meeting, signaling strategic priorities ahead.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.